Clinical Efficacy of Budesonide, Glycopyrrolate, and Formoterol Fumarate Aerosol Combined with an Internet-of-Things Respiratory Rehabilitation Trainer in the Treatment of Patients with Moderate-to-Severe COPD
HUANG Haichen, XIA Qiang, HU Shasha
Department of Respiratory and Critical Care Medicine, Xinyang Central Hospital, Xinyang Henan 464000
Abstract：【Objective】 To investigate the clinical efficacy of budesonide, glycopyrrolate, and formoterol fumarate aerosol combined with an internet-of-things (IoT) respiratory rehabilitation trainer in the treatment of patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). 【Methods】 A total of 96 patients with stable moderate-to-severe COPD admitted to our hospital from July 2024 to June 2025 were selected and divided into a control group and an observation group using a random number table method, with 48 cases in each group. The control group was treated with budesonide, glycopyrrolate, and formoterol fumarate aerosol, while the observation group was additionally treated with an IoT respiratory rehabilitation trainer on the basis of the control group. The clinical efficacy, pulmonary function indicators [peak expiratory flow (PEF), forced expiratory volume in the first second/forced vital capacity (FEV1/FVC)], 6-minute walking distance (6MWD), and quality of life [St. George's Respiratory Questionnaire (SGRQ) score] were compared between the two groups. 【Results】 The total effective rate of the observation group was higher than that of the control group (P<0.05). After 8 weeks of treatment, the PEF and FEV1/FVC of both groups were higher than those before treatment, and the 6MWD was longer than that before treatment. Moreover, the PEF and FEV1/FVC of the observation group were higher than those of the control group, and the 6MWD was longer than that of the control group, with statistically significant differences (P<0.05). The symptom, activity, and impact scores of both groups were lower than those before treatment, and those of the observation group were lower than those of the control group, with statistically significant differences (P<0.05). 【Conclusion】 Budesonide, glycopyrrolate, and formoterol fumarate aerosol combined with an IoT respiratory rehabilitation trainer can further improve pulmonary function and exercise endurance in patients with moderate-to-severe COPD by strengthening respiratory muscle function and optimizing ventilation efficiency, reduce acute exacerbations, enhance quality of life, and demonstrate good safety, making it suitable for clinical promotion
黄海臣, 夏强, 胡莎莎. 布地格福吸入气雾剂联合物联网型呼吸康复训练仪治疗中重度COPD患者的临床疗效[J]. 医学临床研究, 2026, 43(4): 603-606.
HUANG Haichen, XIA Qiang, HU Shasha. Clinical Efficacy of Budesonide, Glycopyrrolate, and Formoterol Fumarate Aerosol Combined with an Internet-of-Things Respiratory Rehabilitation Trainer in the Treatment of Patients with Moderate-to-Severe COPD. JOURNAL OF CLINICAL RESEARCH, 2026, 43(4): 603-606.
2026, Vol. 43 
